For long-term secondary prevention of MI, the use of P2Y12 monotherapy has a borderline advantage over aspirin alone and does not affect bleeding, according to a meta-analysis of nine randomized ...

Please provide your email address to receive an email when new articles are posted on . Valgimigli is deputy chief of interventional cardiology at Cardiocentro Ticino Institute, Lugano, Switzerland.

BARCELONA, Spain—(UPDATED) Aspirin has long been the antiplatelet of choice for long-term secondary prevention in patients with coronary disease, but a meta-analysis of several trials suggests P2Y12 ...

BARCELONA -- Patients with documented coronary artery disease (CAD) saw cardiovascular benefits with P2Y12-inhibitor monotherapy when compared with aspirin alone, according to the PANTHER ...

Please provide your email address to receive an email when new articles are posted on . In a cohort of noncritically ill patients with COVID-19, the addition of a P2Y12 inhibitor to anticoagulation ...

A P2Y12 inhibitor, such as clopidogrel or ticagrelor, might be a better choice than aspirin for antiplatelet monotherapy in patients with coronary artery disease, results of a new meta-analysis ...

Microglia are the resident immune cells of the brain. Increasingly, they are recognized as important mediators of normal neurophysiology, particularly during early development. Here we demonstrate ...

Giving a P2Y12 inhibitor anti-clotting drug to patients with coronary artery disease is associated with lower rates of cardiovascular death, heart attack and stroke compared with traditional aspirin, ...

Background: The initial results for CURRENT-OASIS 7 were presented at the European Society of Cardiology Congress 2009 in Barcelona. To date, final analyses of the study have not been published in a ...

How much do we know about the way blood clots? We already understand the many steps involved in blood clotting in great mechanistic detail. The process of blood vessels closing off in response to ...

Noninferiority was not demonstrated for death and ischemic events between P2Y12 inhibitor monotherapy and dual antiplatelet therapy (DAPT) given for 12 months after stenting in patients with acute ...